 NanoViricides Inc NYSE: NNVC has reported data from animal studies evaluating its broad-spectrum antiviral drug candidate NV-CoV-2 to treat COVID-19 infections. The treatment candidate was well tolerated in safety pharmacology studies in both rat and non-human primate models. 